{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Marinus+Pharmaceuticals", "query": { "sponsor": "Marinus Pharmaceuticals" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Marinus+Pharmaceuticals&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T13:44:24.517Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01963208", "title": "Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Drug Resistant Partial Onset Seizure" ], "interventions": [ { "name": "ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 405, "start_date": "2013-10", "completion_date": "2016-10", "has_results": true, "last_update_posted_date": "2023-02-14", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01963208" }, { "nct_id": "NCT04391569", "title": "Randomized Therapy In Status Epilepticus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Status Epilepticus" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": "2020-12-09", "completion_date": "2024-04-28", "has_results": true, "last_update_posted_date": "2025-05-29", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04391569" }, { "nct_id": "NCT03228394", "title": "A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Depression", "Depressive Disorder", "Depression, Postpartum", "Behavioral Symptoms", "Mood Disorders", "Mental Disorders", "Puerperal Disorders", "Pregnancy Complications", "Postpartum", "PPD" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 91, "start_date": "2017-06-27", "completion_date": "2020-05-10", "has_results": true, "last_update_posted_date": "2023-07-19", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 16, "location_summary": "Little Rock, Arkansas • Costa Mesa, California • Lemon Grove, California + 13 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228394" }, { "nct_id": "NCT00512317", "title": "Open-label Extension to Protocol 1042-0600", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsies, Partial" ], "interventions": [ { "name": "ganaxolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "18 Years to 69 Years" }, "enrollment_count": 123, "start_date": "2007-06", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2023-01-17", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00512317" }, { "nct_id": "NCT01725152", "title": "Ganaxolone Treatment in Children With Fragile X Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fragile x Syndrome" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 59, "start_date": "2012-11", "completion_date": "2016-11-01", "has_results": true, "last_update_posted_date": "2023-04-10", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01725152" }, { "nct_id": "NCT03350035", "title": "Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Status Epilepticus", "Convulsive Status EPILEPTICUS", "Non Convulsive Status Epilepticus", "Epilepsy" ], "interventions": [ { "name": "IV Ganaxolone active", "type": "DRUG" }, { "name": "IV Placebo, non-active", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 17, "start_date": "2018-02-19", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2023-03-09", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 8, "location_summary": "Wilmington, Delaware • Miami, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Wilmington", "state": "Delaware" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03350035" }, { "nct_id": "NCT00442104", "title": "Open-label Extension to Protocol 1042-0500", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infantile Spasms" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Months", "maximum_age": "24 Months", "sex": "ALL", "summary": "4 Months to 24 Months" }, "enrollment_count": 54, "start_date": "2007-01", "completion_date": "2009-03", "has_results": true, "last_update_posted_date": "2024-05-28", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 14, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00442104" }, { "nct_id": "NCT05323734", "title": "Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 129, "start_date": "2022-04-01", "completion_date": "2024-10-14", "has_results": true, "last_update_posted_date": "2025-07-11", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 23, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05323734" }, { "nct_id": "NCT05604170", "title": "Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tuberous Sclerosis Complex" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "65 Years", "sex": "ALL", "summary": "1 Year to 65 Years" }, "enrollment_count": 117, "start_date": "2022-05-16", "completion_date": "2025-04-02", "has_results": true, "last_update_posted_date": "2025-10-01", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 20, "location_summary": "Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05604170" }, { "nct_id": "NCT02358538", "title": "Open-Label PoC Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Ganaxolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Marinus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 30, "start_date": "2015-11-06", "completion_date": "2019-01-04", "has_results": true, "last_update_posted_date": "2023-03-21", "last_synced_at": "2026-09-30T13:44:24.517Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Sacramento, California • San Francisco, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Norcross", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02358538" } ] }